New hope for pancreatic cancer: drug combo tested before and after surgery
NCT ID NCT07131514
First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests a new drug (HRS-4642) combined with standard chemotherapy and an immunotherapy for people with pancreatic cancer that can be surgically removed. The treatment is given before surgery to shrink the tumor and after surgery to prevent return. About 30 adults aged 18-80 with resectable or borderline resectable pancreatic cancer will participate. The goal is to see if the combination is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.